Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667338 | 0.90 | KCNA3 (0.45) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL26759473 | 0.90 | CKS1B (0.47) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL21250402 | 0.87 | KCNA3 (0.43) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL20493902 | 0.85 | KCNA3 (0.41) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL18667340 | 0.85 | KCNA3 (0.41) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL24247901 | 0.85 | KCNA3 (0.46) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL18667343 | 0.84 | KCNA3 (0.41) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL16854336 | 0.83 | ALDH1A1 (0.55) | KCNA3CKS1BSKP1SKP2AKT1 | |
| SCHEMBL19984632 | 0.83 | DRD2 (0.42) | CKS1BSKP1SKP2DRD2 | |
| SCHEMBL1956790 | 0.81 | CYP3A4 (0.49) | KCNA3CKS1BSKP1SKP2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-10968211-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3782626-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782626-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200131168-A1 | HEPATITIS B CORE PROTEIN MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| CN-108347943-A | HEPATITIS B CORE PROTEIN MODULATORS | 组装生物科学股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
| US-10377748-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
| US-10968211-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
| US-20200131168-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KCNA3 4804/4885CKS1B 340/4885SKP1 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.